Novo Nordisk Partners with Anthropic to Enhance Drug Discovery Using AI
Novo Nordisk has partnered with Anthropic to integrate advanced AI models into its drug discovery and development processes. The collaboration will leverage Claude Science and frontier AI models, initially targeting specific scientific challenges where AI can deliver the most impact. Novo is already using Claude to automate clinical-trial report generation, significantly reducing documentation time from months to minutes. The partnership aims to strengthen Novo's R&D pipeline amid growing competition in obesity drugs. Despite a 7% increase in Q2 adjusted sales and an 11% rise in operating profit, the company recorded DKK 6.3 billion in non-cash impairments on pipeline assets, highlighting the need for improved productivity. While AI could potentially accelerate drug development timelines, there is currently no clear financial benefit or specific milestones disclosed from this partnership. The broader use of AI by competitors also raises questions about whether Novo will gain a sustainable advantage.
Tickers: $NVO